Martin & Co. Inc. TN Has $2.90 Million Stake in Johnson & Johnson (NYSE:JNJ)

Martin & Co. Inc. TN grew its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 1.8% in the third quarter, Holdings Channel.com reports. The firm owned 17,743 shares of the company’s stock after purchasing an additional 320 shares during the period. Martin & Co. Inc. TN’s holdings in Johnson & Johnson were worth $2,899,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Johnson & Johnson by 18.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after acquiring an additional 3,912,430 shares in the last quarter. Legal & General Group Plc grew its stake in Johnson & Johnson by 2.3% in the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after purchasing an additional 421,779 shares in the last quarter. FMR LLC increased its position in Johnson & Johnson by 20.8% in the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Johnson & Johnson by 1.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after purchasing an additional 328,297 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Johnson & Johnson by 0.3% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock valued at $1,333,545,000 after buying an additional 24,505 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Trading Down 0.5 %

Shares of JNJ stock opened at $174.00 on Friday. The firm has a market capitalization of $454.92 billion, a P/E ratio of 24.23, a price-to-earnings-growth ratio of 3.45 and a beta of 0.56. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The firm’s fifty day simple moving average is $176.28 and its 200 day simple moving average is $171.61. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion for the quarter, compared to the consensus estimate of $23.44 billion. During the same quarter in the previous year, the firm posted $2.60 EPS. The business’s revenue was up 1.9% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.60%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s payout ratio is presently 62.95%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Raymond James reduced their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, October 19th. Atlantic Securities decreased their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Morgan Stanley cut their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 6th. Bank of America decreased their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research note on Friday, October 14th. Finally, Citigroup raised their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $182.42.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the sale, the vice president now owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the sale, the vice president now directly owns 114,676 shares in the company, valued at approximately $18,864,202. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 300,750 shares of company stock worth $52,311,677. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.